AFP-High (AFP ≥400 ng/mL) advanced HCC for patients who have progressed on or were intolerant to sorafenib
A single infusion of CYRAMZA every 2 weeks1
Premedication for CYRAMZA in patients with AFP-High HCC
- Prior to each CYRAMZA infusion, premedicate all patients with an IV histamine H1 antagonist (eg, diphenhydramine hydrochloride)1
- For patients who have experienced a Grade 1 or 2 infusion-related reaction, also premedicate with dexamethasone (or equivalent) and acetaminophen prior to each CYRAMZA infusion
SELECT IMPORTANT SAFETY INFORMATION
- Prior to the institution of premedication recommendations across clinical trials of CYRAMZA, IRRs occurred in 6 out of 37 patients (16%), including two severe events. The majority of IRRs across trials occurred during or following a first or second CYRAMZA infusion. Symptoms of IRRs included rigors/tremors, back pain/spasms, chest pain and/or tightness, chills, flushing, dyspnea, wheezing, hypoxia, and paresthesia. In severe cases, symptoms included bronchospasm, supraventricular tachycardia, and hypotension.
- Across five clinical studies in 1916 patients with various cancers treated with CYRAMZA in which premedication was recommended or required, the incidence of all Grade IRRs occurred between <1‑9%. Grade 3‑5 IRRs incidence was <1%.
- Monitor patients during the infusion for signs and symptoms of IRRs in a setting with available resuscitation equipment. premedicate prior to each CYRAMZA infusion. Reduce the infusion rate by 50% for Grade 1‑2 IRRs. Permanently discontinue CYRAMZA for Grade 3‑4 IRRs.